Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

Prostate Cancer Clinical Trial

— TACT  

Official title:

Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02766543
• Other study ID #: GCP-10100
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 21, 2016
• Est. completion date: September 30, 2028

Study information

• Verified date: November 2023
• Source: Profound Medical Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

Description:

Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral ultrasound therapy system (TULSA-PRO). The technology is developed for patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue. The treatment is conducted within a MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland. It provides advantages of a non-invasive procedure with short treatment times.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: September 30, 2028
• Est. primary completion date: January 29, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male, age 45 to 80 years

2. Biopsy-confirmed adenocarcinoma of the prostate. Biopsy (minimum 10 cores) obtained = 6 weeks and = 6 months before treatment (or at the discretion of PI and approval by the Sponsor).

3. Clinical stage = T2b 4.1 Gleason score = 3 + 4 (Part I only) 4.2 Gleason score 3+4 (Part II only) *now recruiting

5. PSA = 15 ng/ml

6. Eligible for MRI [Form GCP-10131]

7. Eligible for general anesthesia (ASA category = 3)

8. Prostate volume = 90 cc, on Baseline MRI

9. Prostate size = 5.0 cm in sagittal length, and = 6.0 cm in axial diameter, on Baseline MRI

10. Life expectancy = 10 years

11. No calcifications in the planned ultrasound beam path, or at the discretion of the investigator with approval from the Sponsor.

Exclusion Criteria:

1. Evidence (including Baseline MRI and bone scan) of extracapsular extension, sphincter involvement, seminal vesicle invasion, lymph node invasion or metastases

2. Suspected tumour on Baseline MRI within 3 mm of the prostatic urethra, or in the prostate apex within 3 mm from the sphincter plane

3. Prior definitive treatment of prostate cancer

4. Prior transurethral resection of the prostate (TURP)

5. Use of 5-alpha reductase inhibitors (5-ARIs) or hormone therapy within 3 months prior to the baseline visit. Baseline PSA must be established after a minimum of 3 months following 5-ARIs discontinuation. Additionally, use of 5-ARIs is not permitted following treatment during the study follow-up period.

6. Prostate calcifications > 1 cm in largest diameter, on Baseline Ultrasound

7. Cysts > 1 cm in largest diameter, on Baseline MRI

8. Bleeding disorder (INR > ULN and PTT > ULN)

9. Abnormal coagulation and current anticoagulant therapy. Patients whose anticoagulation therapy can be temporarily reversed within 7 days prior to treatment are eligible. Platelet inhibitors (ie: ASA) and heparin are not exclusion criteria.

10. Acute unresolved Urinary Tract Infection (UTI)

11. Interest in future fertility

12. History of any other malignancy other than skin cancer, or low grade bladder cancer which has been completely resected, within the previous 2 years. Patients that have had curative treatment of a previous malignancy and no recurrence of that malignancy within the past 2 years will be allowed.

13. Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome

14. Patients with diabetes who have evidence of complications from their diabetes, such as end organ sequelae of diabetes or Hemoglobin A1c > 7%.

15. History of any major rectal or pelvic surgery or radiotherapy

16. History of ulcerative colitis or other chronic inflammatory conditions affecting rectum (includes rectal fistula, anal stenosis)

17. Documented clinical prostatitis requiring therapy within 6 months prior to Treatment

18. History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae, urethral stenting, urethral sling, urethroplasty or chronic indwelling urethral catheter

19. Patients with artificial urinary sphincter or any penile implant

20. Severe neurogenic bladder

21. Untreated bladder stones

22. History of acute urinary retention within the last 12 months

23. Active untreated gross hematuria for any cause

24. Post Void Residual (PVR) bladder volume > 250 mL

25. Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder, sometimes referred to as "ball valve" median lobe, determined on Baseline MRI

26. Any prostate related investigational therapy within 6 months of Visit 1

27. History of Parkinson's disease or multiple sclerosis

28. History of drug abuse

29. Known infectious disease including HIV positivity or AIDS-related illness, HBV and HCV

30. Current unilateral or bilateral hydronephrosis

31. Allergy or contraindications to administration of the GI anti-spasmodic drug:

1. Patients in the USA: Glucagon

2. Patients in Canada and Europe: Buscopan (Hyoscine)

32. Contraindications to administration of gadolinium-based MRI contrast agent (e.g. Magnevist), such as chronic, severe kidney disease, acute kidney injury, history of Sickle Cell Disease, history of anemia, or intolerance/allergy to the contrast agent

33. Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• MRI-guided Transurethral Ultrasound Ablation
Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.

Locations

Country	Name	City	State
Canada	London Health Sciences Centre	London	Ontario
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario
Germany	University Hospital of Cologne	Cologne
Germany	Universitätsklinikum Heidelberg (University of Heidelberg, Dept of Urology)	Heidelberg
Netherlands	Radboud University Medical Center	Nijmegen
Spain	ResoFus Alomar (Hospital Universitari De Bellvitge)	Barcelona
United States	Johns Hopkins Medicine	Baltimore	Maryland
United States	University of Chicago	Chicago	Illinois
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Indiana University	Indianapolis	Indiana
United States	University of California Los Angeles	Los Angeles	California
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Yale Cancer Centre	New Haven	Connecticut
United States	William Beaumont Hospital	Royal Oak	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Profound Medical Inc.

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Endpoint - Incidence of treatment-emergent adverse events	Frequency and severity of all adverse events will be evaluated by attribution and reported in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) standard published by the National Cancer Institute (NCI).	1 year
Primary	Efficacy Endpoint - Proportion of patients achieving a PSA nadir = 25% of the pre-treatment baseline value.	Prostate ablation efficacy will be evaluated using the proportion of patients achieving a PSA nadir = 25% of the pre-treatment baseline value.	1 year
Secondary	Erectile Dysfunction Endpoint	Rate of erectile dysfunction, determined by the change from baseline of the proportion of patients with IIEF-5 < 17.	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	Erection Firmness Endpoint	Rate of erection firmness sufficient for penetration, determined by the change from baseline of the proportion of patients with IIEF item 2 = 2.	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	Urinary Incontinence Endpoint	Rate of urinary incontinence, determined by the change from baseline of the proportion of patients with EPIC item 5 = 1 (one or more pads per day).	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	PSA Nadir Endpoint	Proportion of patients achieving PSA nadir = 0.5 ng/ml.	1 year
Secondary	PSA Stability Endpoint	Proportion of patients with PSA = 0.5 ng/ml at the most recent follow-up visit.	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	Prostate Volume Endpoint	Prostate volume reduction, evaluated on MRI between the treatment day and 12-month follow-up visits.	1 year
Secondary	Prostate Biopsy Endpoint	Proportion of patients with negative prostate biopsy at the 12-month follow-up visit, determined by transrectal ultrasound-guided 10-core biopsy.	1 year
Secondary	IPSS Endpoint	Change in International Prostate Symptom Score (IPSS), between the baseline and most recent follow-up visit.	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	IIEF Endpoint	Change in the Erectile Function, Orgasmic Function, Sexual Desire, Intercourse Satisfaction and Overall Satisfaction domains of the International Index of Erectile Function (IIEF-15), between the baseline and most recent follow-up visit.	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	EPIC Endpoint	Change in Urinary, Bowel, Sexual and Hormonal domains of the Expanded Prostate Cancer Index Composite (EPIC), between the baseline and most recent follow-up visit.	At each visit post treatment throughout the total study follow-up - (1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years).
Secondary	Targeting Accuracy Endpoint	Conformal prostate ablation, measured quantitatively between the target prostate volume and the target temperature isotherm on MRI thermometry acquired during the TULSA-PRO procedure, and described using three measures of targeting accuracy (Dice Similarity Coefficient; Over- and under-targeted volumes; Linear targeting in mm).	During treatment
Secondary	CE-MRI Endpoint	Conformal prostate ablation, assessed qualitatively by visualizing the peripheral region of enhancement surrounding the non-perfused volume (NPV) on contrast-enhanced (CE)-MRI acquired immediately after treatment.	Immediately after treatment
Secondary	mpMRI Endpoint	Characterize the effect of the TULSA-PRO ablation on diagnostic multi-parametric prostate MRI (mpMRI), determined using PI-RADS v2 performed at the Baseline and 12-month follow-up visits.	1 year

External Links

•   FDA 510k Summary